カテゴリ： GlobalData, アメリカ, 企業調査

ContraVir Pharmaceuticals Inc (CTRV)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：ContraVir Pharmaceuticals Inc (CTRV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013161
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：51
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that focusses on development and commercialization of targeted antiviral therapies. The company’s pipeline product includes TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its potency and selective index against HBV. The company products are used for the treatment of chronic hepatitis B and shingles. It serves atients and healthcare professionals by developing differentiated therapeutic products ContraVir is headquartered in Edison, New Jersey, the US.

ContraVir Pharmaceuticals Inc (CTRV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 11
Partnerships 12
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 12
Licensing Agreements 13
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 13
Equity Offering 15
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 15
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 16
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 18
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 20
ContraVir Pharma Spin Off from Synergy Pharma 21
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 22
Acquisition 23
ContraVir Pharma Acquires Ciclofilin Pharma 23
ContraVir Pharmaceuticals Inc – Key Competitors 24
ContraVir Pharmaceuticals Inc – Key Employees 25
ContraVir Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Corporate Communications 27
Dec 15, 2016: ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors 27
Sep 21, 2016: ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors 28
Mar 31, 2016: ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer 29
Product News 30
12/08/2016: ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B 30
11/07/2016: ContraVir to Present at AASLDs The Liver Meeting 2016 31
05/25/2016: ContraVir to Showcase CMX157 Data in Poster at the 3rd ANRS HBV Cure Workshop 32
04/19/2016: Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference 33
04/14/2016: ContraVir Invited to Present CMX157 Data at Cambridge Healthtech Institute’s Eleventh Annual Drug Discovery Chemistry Conference 34
04/04/2016: ContraVir Invited to Present CMX157 Data at the Oligonucleotide Therapeutics & Delivery Conference 35
03/03/2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 36
02/04/2016: Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board 37
01/03/2017: ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B 38
Clinical Trials 39
Dec 19, 2016: ContraVir Expands Phase 2a Trial of Tenofovir Exalidex to Include Doses above 100mg 39
Oct 17, 2016: CMX157 Advances Head-to-Head Phase 2a Clinical Study in Hepatitis B Patients with Favorable Recommendation from DSMB 40
Oct 13, 2016: CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread in Hepatitis B Patients 41
Sep 12, 2016: ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B 43
Aug 22, 2016: ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B 44
Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157 45
Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B 46
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 47
Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B 48
Apr 19, 2016: ContraVir Doses First Subject in Phase 1b Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection 49
Mar 29, 2016: ContraVir CMX157 Outperforms Gilead Tenofovir AF Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ContraVir Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ContraVir Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ciclofilin Pharma Raises USD0.05 Million in Venture Financing 11
Center Point Clinical Services Enters into Agreement with ContraVir Pharma 12
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 13
ContraVir Pharma Raises up to USD13.6 Million in Public Offering of Shares 15
ContraVir Pharma Raises USD7 Million in Public Offering of Shares and Warrants 16
ContraVir Pharma Raises USD15 Million in Public Offering of Shares and Warrants 18
ContraVir Pharma Raises USD9 Million in Private Placement of Preferred Shares 20
ContraVir Pharma Spin Off from Synergy Pharma 21
ContraVir Pharma Completes Private Placement Of Securities For US$3 Million 22
ContraVir Pharma Acquires Ciclofilin Pharma 23
ContraVir Pharmaceuticals Inc, Key Competitors 24
ContraVir Pharmaceuticals Inc, Key Employees 25
ContraVir Pharmaceuticals Inc, Subsidiaries 26

★海外企業調査レポート[ContraVir Pharmaceuticals Inc (CTRV)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • The Boston Consulting Group：企業の戦略的SWOT分析
    The Boston Consulting Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Camellia PLC (CAM)：企業の財務・戦略的SWOT分析
    Summary Camellia Plc (Camellia) is a provider of business processing services. The company operates business through agriculture, food service, engineering and investment sectors. Camellia’s agriculture business division offers products such as rubber, maize, citrus, soya and barley, wine, pineapple …
  • Fortum Corporation (FORTUM)：石油・ガス：M&Aディール及び事業提携情報
    Summary Fortum Corp (Fortum) is a clean energy company, which generates, distributes and sells heat and electricity. The company undertakes operation and maintenance of power plants; and offers energy-related services. Fortum's operational assets include hydropower plants, condensing power plants, w …
  • Genethon SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Genethon SA (Genethon) is a non-profit biotherapy research and development organization which designs and develops gene therapy products for rare diseases. The company is developing gene therapy products for the treatment of limb girdle myophaties, duchenne muscular dystrophy, myotubular myo …
  • China Airlines Ltd.：企業の戦略・SWOT・財務情報
    China Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Temasek Holdings (Private) Ltd：企業のM&A・事業提携・投資動向
    Temasek Holdings (Private) Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Temasek Holdings (Private) Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • NuGEN Technologies Inc-医療機器分野：企業M&A・提携分析
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company offers DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DNA …
  • Henry Lamotte Group：戦略・SWOT・企業財務分析
    Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report Summary Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Atria Plc：戦略・SWOT・企業財務分析
    Atria Plc - Strategy, SWOT and Corporate Finance Report Summary Atria Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Edan Instruments Inc (300206)：製品パイプライン分析
    Summary Edan Instruments Inc (Edan Instruments) is a medical equipment provider that offers ECG equipments. The company offers diagnostic ECG, patient monitoring devices, obstetrics and gynaecology monitoring systems, ultrasound imaging, point-of-care testing, in-vitro diagnostics and veterinary equ …
  • Yue Yuen Industrial (Holdings) Limited：企業の戦略・SWOT・財務情報
    Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Link Healthcare Pty Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Link Healthcare Pty Ltd (LINK), a subsidiary of Clinigen Group Plc, is a healthcare solution provider that provides generic products. The company offers therapeutic products, prescription, OTC medicines and medical devices in various therapeutic areas. It offers products such as relistor, an …
  • Galectin Therapeutics Inc (GALT)：企業の財務・戦略的SWOT分析
    Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug c …
  • ERHC Energy Inc (ERHE)：企業の財務・戦略的SWOT分析
    Summary ERHC Energy Inc (ERHC Energy) is an exploration and production company that explores oil and gas assets. The company possesses deep water oil and gas exploration and production interests in the Gulf of Guinea and onshore interests in Republic of Chad and Republic of Kenya. It holds interests …
  • Suntory Beverage & Food Limited：企業の戦略・SWOT・財務情報
    Suntory Beverage & Food Limited - Strategy, SWOT and Corporate Finance Report Summary Suntory Beverage & Food Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Carnival Group International Holdings Ltd：企業のM&A・事業提携・投資動向
    Carnival Group International Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Carnival Group International Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detaile …
  • AstraZeneca Plc (AZN)：企業の財務・戦略的SWOT分析
    AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Agfa HealthCare NV：医療機器：M&Aディール及び事業提携情報
    Summary Agfa HealthCare NV (Agfa HealthCare), a subsidiary of Agfa-Gevaert NV, is a healthcare information technology company, which provides eHealth and digital imaging solutions. It provides software for digital radiography, diagnostic imaging and healthcare IT solutions for hospitals and care cen …
  • Seegene Inc (096530)：医療機器：M&Aディール及び事業提携情報
    Summary Seegene Inc (Seegene) is a diagnostic company that develops molecular diagnostic reagents. The company provides products such as seeplex, anyplex and magicplex among others. It develops ACP, DPO, READ, MuDT and TOCE technologies that enables to detect multiple pathogens in single reactions u …
  • Hexion Inc：企業の戦略的SWOT分析
    Hexion Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆